Hereditary Cancer Screening Panel

Solid Tumor Gene Set

Test includes total exonic coverage for somatic variants arising in 48 genes and six selected translocations that are clinically actionable in a wide range of adenocarcinomas,  squamous cell carcinomas, gliomas, sarcomas and melanomas.

Indications for testing include cancer cases in early stage disease where a mutational profile from multiple genes informs diagnosis or disease stratification, prognosis, or treatment options. For late stage cancers, the test is designed to evaluate options for alternative treatments, including targeted therapies.